Perioperative ctDNA-Based MRD Detection in NSCLC— Letter

Wei, Shixiong; Gao, Xinliang; Tang, Mingbo; Li, Jialin; Zhang, Kewei; Fang, Linan; Dong, Jingyao; Liu, Wei

doi:10.1158/1078-0432.ccr-22-0621

Cited by 1 publication

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, ctDNA concentration increased in patients who underwent chemotherapy, just 4 h after therapy, confirming the post-treatment ctDNA dynamic pattern [ 28 ]. In addition, ctDNA could be a biomarker for the early detection of molecular residual disease and for the prediction of postoperative relapse, thus facilitating the implementation of personalized adjuvant therapy at an early stage [ 29 , 30 ]. However, ctDNA clinical value has been confirmed only in homogenous patients population, and has been mostly investigated in the pre- and post-treatment steps, unlike CTCs that behave independently of this factor [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer

Eslami-S,

Cortés-Hernández,

Sinoquet

et al. 2023

Br J Cancer

View full text Add to dashboard Cite

Background Circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), and extracellular vesicles (EVs) are minimally invasive liquid biopsy biomarkers. This study investigated whether they predict prognosis, alone or in combination, in heterogenous unbiased non-small cell lung cancer (NSCLC) patients. Methods Plasma samples of 54 advanced NSCLC patients from a prospective clinical trial. CtDNA mutations were identified using the UltraSEEK™ Lung Panel (MassARRAY® technology). PD-L1 expression was assessed in small EVs (sEVs) using an enzyme-linked immunosorbent assay. Results At least one ctDNA mutation was detected in 37% of patients. Mutations were not correlated with overall survival (OS) (HR = 1.1, 95% CI = 0.55; 1.83, P = 0.980) and progression-free survival (PFS) (HR = 1.00, 95% CI = 0.57–1.76, P = 0.991). High PD-L1+ sEV concentration was correlated with OS (HR = 1.14, 95% CI = 1.03–1.26, P = 0.016), but not with PFS (HR = 1.08, 95% CI = 0.99–1.18, P = 0.095). The interaction analysis suggested that PD-L1+ sEV correlation with PFS changed in function of CTC presence/absence (P interaction = 0.036). The combination analysis highlighted worse prognosis for patients with CTCs and high PD-L1+ sEV concentration (HR = 7.65, 95% CI = 3.11–18.83, P < 0.001). The mutational statuses of ctDNA and tumour tissue were significantly correlated (P = 0.0001). Conclusion CTCs and high PD-L1+ sEV concentration correlated with PFS and OS, but not ctDNA mutations. Their combined analysis may help to identify patients with worse OS. Trial registration NCT02866149, Registered 01 June 2015, https://clinicaltrials.gov/ct2/show/study/NCT02866149.

show abstract